BioSpace News Archive

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.

Mersana Therapeutics, Inc. (NASDAQ: MRSN) today announced the completion of patient enrollment in UPLIFT, the company’s single-arm registrational trial of UpRi in platinum-resistant ovarian cancer.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2022 and provided a corporate update.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845.

Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3, 2022.

Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its third quarter 2022 financial results on Thursday, November 3, 2022 at 7:00 a.m. ET.